BPC 157 research

What BPC-157 is

BPC-157 is a synthetic pentadecapeptide, a chain of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). It was first described in 1993 by Predrag Sikiric and colleagues at the University of Zagreb as a partial sequence of a larger protein isolated from human gastric juice, which the group called “body protection compound.” It has also been studied under the development codes PL 14736 and PLD-116.

Unlike most short peptides, BPC-157 is reported to be stable in gastric juice. Reviewers attribute this partly to its run of three prolines, which resists non-specific protease cleavage. In rat studies it is broken down quickly once absorbed, with an elimination half-life reported below 30 minutes.

What researchers study

Almost all published BPC-157 work is preclinical, in rodent models. The largest bodies of literature cover gastrointestinal lesions (including alcohol- and NSAID-induced damage), tendon, ligament and muscle injury models, skin wound models, and blood-vessel formation. Proposed mechanisms under investigation include the nitric oxide system and VEGFR2 signalling in angiogenesis, and tendon fibroblast outgrowth and migration (Chang et al., 2011).

Human evidence is thin. A Phase I safety and pharmacokinetics trial in healthy volunteers (NCT02637284) began in 2015, but its results were never reported. Two 2025 reviews of the orthopaedic literature (Vasireddi et al.; McGuire et al.) conclude that controlled clinical data are lacking, which is why the compound remains a research material.

Regulatory status (October 2026)

BPC-157 is not approved by the FDA or any other major regulator. In April 2026 it was removed from FDA’s Category 2 list of bulk substances for compounding after its nomination was withdrawn. On July 23, 2026, FDA’s Pharmacy Compounding Advisory Committee voted 8–6 (one abstention) to recommend adding it to the Section 503A bulks list, reviewing it for ulcerative colitis. The vote is advisory; formal rulemaking has not taken place.

BPC-157 vs. TB-500

BPC-157 and TB-500 are often studied side by side but are unrelated molecules. BPC-157 derives from a gastric protein; TB-500 is a synthetic fragment based on thymosin beta-4, an actin-binding protein found in most cells. See the TB-500 research page and our BPC-157 + TB-500 kit guide.